Summary
Bevacizumab has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Cancer. ClinicalTrials.gov lists 8 registered trials linking Bevacizumab to Cancer: 2 are currently recruiting; 2 are active or not yet recruiting; 3 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT05476939). The largest enrolment is 495 participants (NCT06400472). Registration activity spans 2001 to 2026. The literature layer holds 13 publications for this pair: 5 Cochrane reviews, 3 meta-analyses and 5 clinical trial publications. The dated items are from 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Cancer ranks 1226 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Spontaneous regression is rare (<0.5% of cases); 5-year survival without treatment: <5% for advanced NSCLC; ~20% for stage I-II with surgery.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 74.5 (trials 24.5, literature 30.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 2 recruiting, 2 active / not yet recruiting, 3 completed, 1 other |
| Linked publications | 13 (5 Cochrane reviews, 5 clinical trial publications, 3 meta-analyses) |
| Agent type | Biologic |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT05476939 | Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0 2022 | recruiting | Phase 3 | 433 |
| NCT01492673 | Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma 2011 | completed | Phase 2 | 9 |
| NCT00015951 | Bevacizumab, Cytarabine, and Mitoxantrone on Treating Patients With Hematologic Cancers 2001 | completed | Phase 2 | — |
| NCT07117877 | Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer 2025 | not yet recruiting | Phase 2 | 33 |
| NCT00755157 | Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer 2008 | withdrawn | Phase 2 | — |
| NCT06400472 | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors 2024 | recruiting | Phase 1 | 495 |
| NCT00952029 | Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer 2010 | completed | PHASE2, PHASE3 | 492 |
| NCT07637851 | Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer 2026 | not yet recruiting | PHASE1, PHASE2 | 43 |
Published literature
- Clinical trial publication Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trialRovers KP, Bakkers C, van den Heuvel TBM et al. · The Lancet. Oncology · 2026 · PMID 42372745
- Clinical trial publication CT Perfusion Blood Flow Provides an Early Response Marker for Progression-free Survival in a Prospective Randomized Clinical Trial of Metastatic Renal Cell CarcinomaNg CS, Chen Y, Wei W et al. · Technology in cancer research & treatment · 2026 · PMID 42308169
- Clinical trial publication Serplulimab Plus Chemotherapy, with or without HLX04, versus Chemotherapy as First-Line Treatment for Nonsquamous NSCLC: Final Survival Analysis of the Phase III ASTRUM-002 StudyHao X, Wang L, Hao Y et al. · Cancer communications (London, England) · 2026 · PMID 42282892
- Clinical trial publication Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinomaIden CR, Øgaard N, Mustafa SM et al. · Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026 · PMID 42176235
- Clinical trial publication Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clustersHaddad G, Guo J, Xi Y et al. · The Journal of clinical investigation · 2026 · PMID 42138077
- Cochrane review First-line immunotherapy for advanced hepatocellular carcinoma: a network meta-analysis of randomized trials with overall and HBV/HCV-stratified efficacy and safetyChen W, Chen B, Hu C et al. · Frontiers in immunology · 2026 · PMID 42220514
- Cochrane review Efficacy and safety of targeted therapies for glioblastoma: a systematic review and network meta-analysisLiu D, Liu Y, Ci Y et al. · BMC cancer · 2026 · PMID 42151869
- Cochrane review Advancements in Glioblastoma Multiforme Treatment: A Comprehensive Systematic Review and Meta-AnalysisAgboola K, Khafaji F, Chaurasia B et al. · Brain and behavior · 2026 · PMID 42050865
- Cochrane review The Promise of Chemotherapy-Free Strategies in Advanced Driver-Negative NSCLC: A Systematic Review and Network Meta-Analysis of Antiangiogenic Combination TherapiesLi Z, Zhao W, Guo W et al. · Cancer medicine · 2026 · PMID 41952287
- Cochrane review A Network Meta-Analysis Comparing the Efficacy of Lenvatinib, Atezolizumab plus Bevacizumab, and Sorafenib in the Treatment of Unresectable Hepatocellular CarcinomaRemitha NPSI, Sasmana IGAP, Kusuma IKWA et al. · Asian Pacific journal of cancer prevention : APJCP · 2026 · PMID 41945955
- Meta-analysis Treatments for metastatic non-small cell lung cancer: a pathways pilot with systematic review, evidence synthesis and economic modelPedder H, Manzano CL, Claxton L et al. · Health technology assessment (Winchester, England) · 2026 · PMID 42246395
- Meta-analysis First-line immunotherapy with or without PARP inhibitors in advanced ovarian cancer: A meta-analysis including bevacizumab use, molecular status, and PD-L1 expressionMarchetti C, Sassu CM, Cefaliello A et al. · Critical reviews in oncology/hematology · 2026 · PMID 42155872
- Meta-analysis Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapyWang X, Zhang Y, Wang C et al. · Frontiers in immunology · 2026 · PMID 42079658
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Bevacizumab approved for Cancer?
Bevacizumab has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Cancer would be drug repurposing rather than first-in-human development. This does not mean it is approved for Cancer. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Bevacizumab in clinical trials for Cancer?
ClinicalTrials.gov lists 8 registered trials linking Bevacizumab to Cancer: 2 are currently recruiting; 2 are active or not yet recruiting; 3 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 3 (NCT05476939). The largest enrolment is 495 participants (NCT06400472). Registration activity spans 2001 to 2026.
What does the evidence show for Bevacizumab in Cancer?
Bevacizumab has both completed registered trials and synthesis-level publications linked to Cancer. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.